40 search results for: disease progression

Missing material
Content temporarily unavailable
Impact of Delayed EoE Diagnosis on Disease Progression and QoL

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

Missing material
Content temporarily unavailable
Pediatric EoE: An Interactive Learning Symposium

Professors Oliva and Hӧrning explore the journey of pediatric patients with EoE through diagnosis, disease progression, and treatment.

Missing material
Content temporarily unavailable
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.

Missing material
Content temporarily unavailable
Worsening Disease Results in a Vicious Cycle of COPD

Uncover the complex interconnected factors that drive the progressive and worsening vicious cycle of COPD.

Missing material
Content temporarily unavailable
UEGW 2024 | WHY Is Long-Term Management of EoE Important?

Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

Missing material
Content temporarily unavailable
Gap in Care Leads to Progression of Fibrosis in EoE

Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.

Missing material
Content temporarily unavailable
Managing the Risk of Fibrostenosis in EoE

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Missing material
Content temporarily unavailable
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

Missing material
Content temporarily unavailable
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

Missing material
Content temporarily unavailable
Type 2 Inflammation

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Lio, MD and Dr. Amy Paller, MD discusses the multifaceted nature of atopic diseases, including environmental triggers, key Type 2 inflammatory mechanisms, and associated health risks, to understand the importance of early intervention in managing and potentially modifying disease progression.

Missing material
Content temporarily unavailable
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

Missing material
Content temporarily unavailable
Atopic Dermatitis: Pathomechanisms: Clarifying Perspectives and Misconceptions

Join Lisa Swanson, MD, and Gina Mangin, MPAS, PA-C, for an in-depth discussion on the immunopathogenesis of atopic dermatitis (AD), highlighting the central role of key type 2 inflammatory pathways in disease development and progression. This program explores how these pathways contribute to clinical manifestations across the AD spectrum and addresses common perceptions and misconceptions surrounding AD pathomechanisms, offering clarifying insights to support informed clinical decision-making.